Intensive Care Unit Mortality Risk Prediction And Quality Measurement: The Impact Of Code Status And Sepsis As Risk Adjustors

Author(s):  
Erika J. Yoo ◽  
Mitzi L. Dean ◽  
Ted Clay ◽  
R. A. Dudley
2021 ◽  
Vol 5 (2) ◽  
pp. 13
Author(s):  
AmalA Al Khalfan ◽  
AhmedA Al Ghamdi ◽  
Stephanie De Simone ◽  
YasserH Hadi

2014 ◽  
Vol 29 (6) ◽  
pp. 948-954 ◽  
Author(s):  
Shailesh Bihari ◽  
Sandra L. Peake ◽  
Michael Bailey ◽  
David Pilcher ◽  
Shivesh Prakash ◽  
...  

2021 ◽  
Author(s):  
Eugene T. Y. Ang ◽  
Mila Nambiar ◽  
Yong Sheng Soh ◽  
Vincent Y. F. Tan

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Wim Van Biesen ◽  
Johan Steen ◽  
Johan Decruyenaere ◽  
Dominique Benoit ◽  
Eric Adriaan J Hoste ◽  
...  

Abstract Background and Aims The reported associated mortality risks of Acute Kidney Injury (AKI) in the intensive care unit (ICU) are variable. Although the Kidney Disease Improving Global Outcome (K-DIGO) improved harmonisation of the definition, there is remaining variability in the actual implementation of this AKI definition, with variable use of the urinary output (UO) criterion, and different interpretations of the baseline serum creatinine (Screa). This hampers progress of our understanding of the clinical concept AKI and leads to confusion and unclarity when interpreting models to predict AKI associated outcomes. With the advent of big data and artificial intelligence based decision algorithms, this problem will only become more of interest, as the user will not know what exactly the construct AKI in the application used means. Therefore, we intended to explore the impact of different interpretations of the Screa and the UO criterium as presented in the K-DIGO definition on the associated ICU mortality risk of AKI stage 2 in the ICU. Method We included all patients of an electronic health data system applied in a tertiary ICU between 2013 and 2017. Sequential Organ Failure Assessment (SOFA) score was calculated, and gender, age, weight and mortality at ICU and in hospital were extracted. All serum creatinine (sCrea) values during ICU stay and hospitalisation were extracted, as were UO data, with their time stamps. In addition, all Screa data up to 1 year before ICU admission were retrieved from a dataset external to ICU. AKI was defined according to KDIGO stage 2, using different possible interpretations of the Screa and/or the UO criterion. For the evolution of Screa as compared to a baseline value, we either used a value directly available to ICU staff (def 1), a presumed eGFR of 75ml/min (def 2), the first available value after admission to ICU (def 3), the lowest value during the current hospitalisation before ICU admission (def 4), the lowest value before the hospitalisation episode as found in an external dataset (def 5). For the UO criterion, we used either (in line with K-DIGO stage 2) a UO below 6ml/kg during a 12 hour block (def 6) or a UO below 0.5ml/kg/hour during each of 12 consecutive one hour intervals (def 7). Definition 8 and 9 identified patients who complied with at least one out of the Screa criteria 1-5 (def 8) or out of the UO criteria (def 9). Definition 10 identified patients who complied both with at least one Screa and one UO criterium. Results Our dataset comprised 16433 admissions (34.7% female, age 60.7±16.4 years). Overall, 8.1% of patients died in Intensive Care Unit (ICU). The SOFA score at admission was 6.9±4.1. The mortality risk associated with AKI according to the stage 2 definition of K-DIGO varied according to the interpretation of the diagnostic criteria (table). Most important, associated mortality risk was comparable whether a UO (RR 2.31, 95% CI 1.90-2.81) or a Screa (RR 2.00, 95% CI 1.57-2.55) criterium was used, and was highest in patients who complied with both at least one UO and one Screa criterium (RR 7.28, 95% CI 6.12-8.65). Conclusion Unclarity on the actual interpretation of the Screa and UO criteria used in the K-DIGO definition of AKI leads to substantial differences in AKI associated mortality risk. Omitting the UO criterium leads to substantial underestimation of associated risk.


2018 ◽  
Vol 122 (10) ◽  
pp. 1773-1778 ◽  
Author(s):  
Jacob C. Jentzer ◽  
Dennis H. Murphree ◽  
Brandon Wiley ◽  
Courtney Bennett ◽  
Michael Goldfarb ◽  
...  

2020 ◽  
Vol 224 ◽  
pp. 57-64 ◽  
Author(s):  
Jacob C. Jentzer ◽  
Sean van Diepen ◽  
Dennis H. Murphree ◽  
Abdalla S. Ismail ◽  
Mark T. Keegan ◽  
...  

2020 ◽  
pp. 107815522091078
Author(s):  
Emily McDonnell ◽  
Reagan Collins ◽  
Mike Hernandez ◽  
Anne Rain T. Brown

Background Corticosteroids are used as adjunctive treatment of critical illness-related corticosteroid insufficiency in patients with septic shock. This study aims to compare the impact of hydrocortisone versus methylprednisolone on duration of septic shock in critically ill oncology patients. Methods Single-center, retrospective cohort study of adult patients receiving hydrocortisone ≥200 mg/day or methylprednisolone ≥40 mg/day with septic shock. The primary outcome was time to shock reversal defined as time to systolic blood pressure ≥90 mmHg without vasopressors for ≥24 h. Results Eighty-eight patients were included, 49 patients received hydrocortisone and 39 patients received methylprednisolone. Solid tumor malignancy was more common in the hydrocortisone group, while hematological malignancy was more common in the methylprednisolone group (p = 0.009). Time to shock reversal was similar between hydrocortisone and methylprednisolone groups (72.4 versus 70.4 h; p = 0.825). Intensive care unit mortality occurred in 51.02% versus 53.85% of patients in hydrocortisone versus methylprednisolone, respectively (p = 0.792). Patients who received methylprednisolone had higher rates of mechanical ventilation (89.74% versus 55.1%, p < 0.001) and longer intensive care unit and hospital lengths of stay (4.2 versus 11.4 days and 14.3 versus 25.7 days; p < 0.001) compared to hydrocortisone. No differences were seen in incidence of steroid-related adverse effects between groups. Conclusions In oncology patients with septic shock, the use of hydrocortisone versus methylprednisolone does not appear to affect time to shock reversal.


Sign in / Sign up

Export Citation Format

Share Document